Representing Taxotere® Hair Loss Victims Nationwide
Taxotere® (docetaxel) has been used in the treatment of non-small cell lung cancer, advanced stomach cancer, head and neck cancer, metastatic prostate cancer, and breast cancer. In fact, it is the most widely used breast cancer drug in its class, prescribed to almost 75 percent of cancer patients.
However, cancer survivors are finding out the hair loss they thought was temporary may, in fact, be permanent hair loss if treated with the drug Taxotere®.
The defective drug lawyers at Reeves & Mestayer are currently accepting lawsuits involving permanent hair loss caused by Taxotere®. For more information, please call us today at 228-374-5151 or toll free 1-855-558-2977.
Taxotere® has been linked to permanent hair loss, known as Alopecia. There are three types of alopecia: Alopecia areata (loss of hair usually from the scalp in round patches), Alopecia totalis (loss of all head hair), and Alopecia universalis (loss of hair on scalp and body). Alopecia is caused as a result of an autoimmune disorder which causes the body’s white blood cells to attack hair follicles. Once contracted, Alopecia is permanent.
Taxotere® is an anti-cancer chemotherapy drug classified as a “plant alkaloid,” a “taxane,” and an “antimicrotubule agent.” The two types of taxanes are Paclitaxel and Taxotere. Taxotere® (docetaxel) is a type of human-made taxane chemotherapy medicine that works by damaging the structure or the “skeleton” that supports cancer cells, and stopping the cancer from growing and dividing.
Taxotere® is manufactured by Sanofi-Aventis and has been sold in the United States since 1999. The investigation into this drug is in its early stages and lawsuits have been filed nationwide against the manufacturer, Sanofi-Aventis. These lawsuits claim intentional misleading on the part of Sanofi-Aventis and failure to warn of permanent hair loss.
- In April of 2009, the U.S. Food and Drug Administration (FDA) warned Sanofi-Aventis of using misleading promotional materials.
- In 2010, Sanofi-Aventis reported Taxotere® had been used to treat more than 1.5 million patients.
- Five years later, in December, 2015, the FDA required Sanofi-Aventis to change the warning label to include a new warning of permanent hair loss.
If you are or a love one has suffered harm from use of Taxotere®, we urge you to consult with one of our attorneys for a free case evaluation. Reeves & Mestayer, PLLC are experienced attorneys who will work for you. There is no fee unless we accept your case and a recovery is made for you. You can contact us here on our website or by phone at 1-855-558-2977.